Predictors of Immune Reconstitution Syndrome in Organ Transplant Recipients With Cryptococcosis: Implications for the Management of Immunosuppression
Open Access
- 9 September 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (1) , 36-44
Abstract
Authors determined variables that pose a risk for immune reconstitution syndrome (IRS) and have shown that discontinuation of calcineurin inhibitors was independently associated with 5-fold increased risk of IRS in transplant recipients with cryptococcosis. Background. Risk factors including how changes in immunosuppression influence the occurrence of immune reconstitution syndrome (IRS) in solid organ transplant (SOT) recipients with cryptococcosis have not been fully defined. Methods. SOT recipients with cryptococcosis were identified and followed for 12 months. IRS was defined based on previously proposed criteria. Results. Of 89 SOT recipients, 13 (14%) developed IRS. Central nervous system (CNS) disease (adjusted odds ratio [AOR], 6.23; P = .03) and discontinuation of calcineurin inhibitor (AOR, 5.11; P = .02) were independently associated with IRS. Only 2.6% (1/13) of the patients without these risk factors developed IRS compared with 18.8% (6/32) with 1 risk factor, and 50% (6/12) with both risk factors (χ2 for trend, P = .0001). Among patients with CNS disease, those with neuroimaging abnormalities (P = .03) were more likely to develop IRS, irrespective of serum or CSF cryptococcal antigen titers and fungemia. Graft rejection after cryptococcosis was observed in 15.4% (2/13) of the patients with IRS compared with 2.6% (2/76) of those without IRS (P = .07). Conclusions. We determined variables that pose a risk for IRS and have shown that discontinuation of calcineurin inhibitors was independently associated with 5-fold increased risk of IRS in transplant recipients with cryptococcosis.Keywords
This publication has 32 references indexed in Scilit:
- Cryptococcosis in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Central Nervous System Cryptococcosis in Solid Organ Transplant Recipients: Clinical Relevance of Abnormal Neuroimaging FindingsTransplantation, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Calcineurin Inhibitor Agents Interact Synergistically with Antifungal Agents In Vitro against Cryptococcus neoformans Isolates: Correlation with Outcome in Solid Organ Transplant Recipients with CryptococcosisAntimicrobial Agents and Chemotherapy, 2008
- Cryptococcus neoformansin Organ Transplant Recipients: Impact of Calcineurin‐Inhibitor Agents on MortalityThe Journal of Infectious Diseases, 2007
- An Immune Reconstitution Syndrome-Like Illness Associated withCryptococcus neoformans Infection in Organ Transplant RecipientsClinical Infectious Diseases, 2005
- The damage-response framework of microbial pathogenesisNature Reviews Microbiology, 2003
- Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and OutcomeEmerging Infectious Diseases, 2001
- Cryptococcus neoformansInfection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and OutcomeEmerging Infectious Diseases, 2001